Brink Therapeutics Secures €3.5 Million in Seed Funding for Advanced Gene Therapy
Deal News | Apr 17, 2025 | Goodwin
Brink Therapeutics, a Paris-based biotech startup known for its cutting-edge gene therapy solutions, has successfully raised €3.5 million in seed funding. The capital injection was led by notable investors including Kurma Partners and Breega, alongside Kima Ventures, Plug and Play Ventures, and several prominent business angels from the healthcare and AI sectors. This funding round marks a significant milestone for Brink Therapeutics, as it aims to revolutionize the gene therapy landscape through a blend of directed evolution, metagenomic exploration, and artificial intelligence. By designing enzymes capable of precise DNA editing, Brink Therapeutics seeks to develop safer and more effective treatments, thus expanding the possibilities within the field of gene therapies.
Sectors
- Biotechnology
- Venture Capital
- Healthcare
Geography
- France – Brink Therapeutics is based in Paris, and the investment round was led by Paris-based firms, indicating the central role of France in this transaction.
Industry
- Biotechnology – Brink Therapeutics operates in the biotechnology sector, focusing on gene therapy and enzyme design using advanced technologies like artificial intelligence.
- Venture Capital – Kurma Partners, Breega, Kima Ventures, and other investors are active in the venture capital industry, providing initial funding to innovative startups like Brink Therapeutics.
- Healthcare – The investment and innovation by Brink Therapeutics are relevant to the healthcare industry, particularly in advancing therapeutic solutions through gene therapy.
Financials
- €3.5 Million – The amount raised by Brink Therapeutics in its seed financing round from various investors.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Brink Therapeutics | Target Company | Company | A Paris-based biotech startup focused on developing innovative gene therapies using a combination of directed evolution, metagenomic exploration, and AI. |
| Kurma Partners | Investor | Company | A venture capital firm that led the seed funding round for Brink Therapeutics, specializing in healthcare and life sciences investments. |
| Breega | Investor | Company | A venture capital firm that participated in the seed funding round for Brink Therapeutics, known for investing in innovative startups. |
| Goodwin | Legal Advisor | Company | The Paris Life Sciences and Technology team at Goodwin provided legal advice on the fundraising process for Kurma Partners and Breega. |
| Kima Ventures | Investor | Company | One of the participating investors in the Brink Therapeutics seed funding round, known for supporting early-stage startups. |
| Plug and Play Ventures | Investor | Company | A venture capital firm involved in the seed funding round, focused on a wide array of industries including healthcare. |
| Business Angels | Investor | People | Individual investors in the healthcare and artificial intelligence sectors who participated in the funding round for Brink Therapeutics. |